Clinical Pharmacology of Electronic Nicotine Delivery Systems (ENDS): Implications for Benefits and Risks in the Promotion of the Combusted Tobacco Endgame.
Clinical Pharmacology of Electronic Nicotine Delivery Systems (ENDS): Implications for Benefits and Risks in the Promotion of the Combusted Tobacco Endgame.
复制标题
DOI：
10.1002/jcph.1915
复制
发表时间：
2021-08
影响因子：
2.9
通讯作者：
Liakoni, Evangelia
中科院分区：
文献类型：
--
作者：
Benowitz, Neal L.;St Helen, Gideon;Liakoni, Evangelia
电子尼古丁输送系统(END)，如电子烟和加热烟草产品，是一种新型的电池供电装置，无需燃烧烟草即可输送尼古丁。由于吸烟是由尼古丁成瘾持续的，有毒的燃烧产物是吸烟的有害影响的主要原因，与传统香烟相比，END可用于促进戒烟，同时使使用者暴露在较低水平的毒物中。目前从临床和观察研究中获得的证据表明，电子烟作为戒烟辅助工具具有潜在的作用，尽管许多人在戒烟很长时间后仍在使用电子烟。尼古丁和毒物的输送因设备不同而有很大不同，并取决于电子液体配方的特点。由于吸烟者倾向于滴定他们的尼古丁摄入量以保持他们想要的药理效果，当使用END作为戒烟辅助时，需要考虑设备和液体的特性。可能限制其使用的因素是这些产品目前仍不清楚的长期安全性，以及对在年轻人中广泛使用的担忧。讨论了临床药理学数据对香烟终局的影响以及美国食品和药物管理局的监管。
Electronic nicotine delivery systems (ENDS) such as e-cigarettes and heated tobacco products are novel battery-operated devices that deliver nicotine without combustion of tobacco. Since cigarette smoking is sustained by nicotine addiction and the toxic combustion products are mainly responsible for the harmful effects of smoking, ENDS could be used to promote smoking cessation while exposing users to lower levels of toxicants compared to conventional cigarettes. The currently available evidence from clinical and observational studies indicate a potential role of e-cigarettes as smoking cessation aids, although many continue to use e-cigarettes long after quitting smoking. Nicotine and toxicant delivery vary considerably by device and depend on characteristics of the e-liquid formulation. Since smokers tend to titrate their nicotine intake to maintain their desired pharmacologic effects, device and liquid characteristics need to be considered when using ENDS as an aid to quit smoking. Factors potentially limiting their use are the currently still unknown long-term safety of these products and concerns regarding widespread use among youth. Implications of clinical pharmacology data on ENDS for the cigarette endgame and regulation by the U.S. Food and Drug administration are discussed.
登录
查看更多内容
影响因子：
37.8
作者：
Bhatnagar A;Whitsel LP;Ribisl KM;Bullen C;Chaloupka F;Piano MR;Robertson RM;McAuley T;Goff D;Benowitz N;American Heart Association Advocacy Coordinating Committee, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Quality of Care and Outcomes Research
通讯作者：
American Heart Association Advocacy Coordinating Committee, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Quality of Care and Outcomes Research
DOI：
10.1158/1055-9965.epi-11-0644
发表时间：
2012-05
期刊：
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子：
--
作者：
Benowitz NL;Dains KM;Hall SM;Stewart S;Wilson M;Dempsey D;Jacob P 3rd
通讯作者：
Jacob P 3rd
影响因子：
168.9
作者：
Bullen, Christopher;Howe, Colin;Walker, Natalie
通讯作者：
Walker, Natalie
影响因子：
5.3
作者：
Antoniewicz, Lukasz;Bosson, Jenny A.;Lundback, Magnus
通讯作者：
Lundback, Magnus
影响因子：
3.2
作者：
Balakumar, Pitchai;Kaur, Jagdeep
通讯作者：
Kaur, Jagdeep